News

The clinical contract research and development organization Sanos Group acquires Austrian NeuroScios, which is a contract research organization (CRO) focusing on Alzheimer's and other diseases of the central nervous system. The acquisition is part of Sanos Group's strategic development as a multi-niche CRO, where Sanos is now adding a third specialist area to the two current scientific areas of osteoarthritis and dermatology.

Asger brings with him 15+ years of clin ops experience and will add senior expertise useful in both our daily operations and sponsor interactions.

The paper is entitled “Joint biomarker response to mechanical stimuli in osteoarthritis - A scoping review”, and is authored by: Jonathan J Bjerre-Bastos, Nizar Hamrouni, Yves Henrotin, Christian S Thudium and Asger R Bihlet

Our Chief Scientific Officer, Asger Bihlet, will be a speaker on the OARSI Live Webinar on Phenotyping. The webinar is entitled: “Challenges and Opportunities of Phenotyping in Osteoarthritis”, and will be held Wednesday, January 18, 2023, 8:00-9:00 am EST.

NBCD will be participating in the virtual part of JPM 2023, represented by Chief Commercial Officer, Casper Clemmensen, who will be sharing our unique expertise and insights on OA.

Sanos Group has relocated! The new office environment supports our close collaboration across the teams and offers a range of meeting rooms, areas for shorter informal meetings, soft seating, a quiet zone, and a shared café/canteen – all in modern décor with plenty of colors. The new offices hold Sanos Group and NBCD employees.

The paper is entitled “Impact of Monitoring Approaches on Data Quality in Clinical Trials - A Cross-Study Comparison of Risk-Based Monitoring and Classic Monitoring”, and is authored by: Jeppe Ragnar Andersen, Christoffer von Sehested, Inger Byrjalsen, Sara Popik, Anne Bo Follin, and Asger Bihlet.

For the third year in a row, NBCD is the proud receiver of the Danish Business Award: A Børsens Gazelle. In 2022, we have welcomed 14 new team members in Denmark alone and we look forward to expanding even further in 2023.

The NBCD science-team will be present at this year's American College of Rheumatology Convergence on 11-14 November in Philadelphia, USA. Here, they will present the Ignite poster: “Antihistamine Use and Structural Progression of Knee OA: A Post-Hoc Analysis of Two Phase 3 Clinical Trials”.